Optimizing anti-TNF treatments in inflammatory bowel disease

Autoimmunity Reviews

Volumn 13, Issue 1, 2014, Pages 24-30

  Ben Horin, Shomron ^a   Kopylov, Uri ^a   Chowers, Yehuda ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Anti TNF antibodies; Inflammatory bowel disease; Therapy

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CASPASE 9; DRUG ANTIBODY; FAS LIGAND; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; RHEUMATOID FACTOR; TUMOR NECROSIS FACTOR INHIBITOR;

ANTIGEN ANTIBODY COMPLEX; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CROHN DISEASE; DISEASE DURATION; DISEASE PREDISPOSITION; DRUG CLEARANCE; DRUG TREATMENT FAILURE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; HUMAN; IMMUNOGENICITY; INJECTION; IRRITABLE COLON; MONOTHERAPY; MULTICENTER STUDY (TOPIC); RADIOIMMUNOASSAY; REMISSION; RETICULOENDOTHELIAL SYSTEM; REVIEW; RHEUMATOID ARTHRITIS; SMOKING; SMOKING CESSATION; ULCERATIVE COLITIS; WATCHFUL WAITING;

ANTI-TNF ANTIBODIES; ANTIBODIES TO ADALIMUMAB; ANTIBODIES TO INFLIXIMAB; ATA; ATI; CD; CROHN'S DISEASE; IBD; INFLAMMATORY BOWEL DISEASE; LOR; LOSS OF RESPONSE; THERAPY; UC; ULCERATIVE COLITIS;

ANTIBODIES; HUMANS; IMMUNOMODULATION; INCIDENCE; INFLAMMATORY BOWEL DISEASES; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84886946831     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2013.06.002     Document Type: Review

References (60)

1. Hanauer S., Feagan B., Lichtenshtein G., et al. Maintenance infliximab for Crohn's Disease: the ACCENT 1 randomized trial. Lancet 2002, 359:1541-1549.
2. Atzeni F., Doria A., Carrabba M., Turiel M., Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev 2007, 6:529-536.
3. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010, 4:355-366.
4. Papagoras C., Voulgari P.V., Drosos A.A. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis. Autoimmun Rev 2010, 9:574-582.
5. Rutgeerts P., Sandborn W.J., Feagan B.J., et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005, 353:2462-2476.
6. Sands B.E., Anderson F.H., Bernstein C.N., et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004, 350:876-885.
7. D'Haens G.R., Panaccione R., Higgins P.D., et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?. Am J Gastroenterol 2011, 106:199-212.
8. Caporali R., Pallavicini F.B., Filippini M., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 2009, 8:274-280.
9. Siegel C.A., Melmed G.Y. Predicting response to anti-TNF agents for the treatment of Crohn's disease. Ther Adv Gastroenterol 2009, 2:244-251.
10. Agmon-Levin N., Lian Z., Shoenfeld Y. Explosion of autoimmune disease and the mosaics of old and novel factors. Cell Mol Immunol 2011, 8:189-192.
11. Ingegnoli F., Favalli E.G., Meroni P.L. Does polymorphysm of genes coding for pro-inflammatory mediators predict the clinical response to TNF alpha blocking agents? A review analysis of the literature. Autoimmun Rev 2011, 10:460-463.
12. Ho G.T., Smith L., Aitken S., et al. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008, 27:308-315.
13. Swaminath A., Ullman T., Rosen M., et al. Early clinical experience with adalimumab in treatment of inflammatory bowel disease with infliximab-treated and naïve patients. Aliment Pharmacol Ther 2009, 29:273-278.
14. Allez M., Vermeire S., Mozziconacci N., et al. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies. Aliment Pharmacol Ther 2010, 31:92-101.
15. Ben-Horin S., Chowers Y. Loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011, 33:987-995.
16. Gisbert J.P., Panes J.J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009, 104:760-767.
17. Billioud V., Sandborn W.J., Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn's disease. A systematic review. Am J Gastroenterol 2011, 106:674-684.
18. Lichtenstein G.R., Yan S., Bala M., et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005, 128:862-869.
19. Colombel J.F., Sandborn W.J., Rutgeerts P., et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007, 132:52-65.
20. Schnitzler F., Fidder H., Ferrante M., et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009, 58:492-500.
21. Vermeire S., Noman M., Van Assche G., et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut 2007, 56:1226-1231.
22. Van Assche G., Magdelaine-Beuzelin C., D'Haens G., et al. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868.
23. Feagan B.G., McDonald J., Ponich T., et al. A randomized trial of methotrexate (MTX) in combination with infliximab (IFX) for the treatment of Crohn's disease (CD). Gastroenterology 2008, 134:682c.
24. Colombel J.F., Sandborn W.J., Reinisch W., et al. SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010, 362:1383-1395.
25. Panaccione R., Sandborn W.J., Gordon G., et al. Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. J Crohns Colitis 2011, 5:2.
26. Sokol H., Seksik P., Carrat F., et al. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010, 59:1363-1368.
27. van der Valk M.E., van Oijen M.G., Ammerlaan M., Siersema P.D., Oldenburg B. Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators. Gut 2012, 61:324-325.
28. Bazzani C., Filippini M., Caporali R., et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. Autoimmun Rev 2009, 8:260-265.
29. Ben-Horin S., Yavzori M., Katz L., et al. The immunogenic part of Infliximab is the F(ab')2 fragment, but measuring antibodies to the intact Infliximab molecule is more clinically useful. Gut 2011, 60:41-48.
30. Rojas J.R., Taylor R.P., Cunningham M.R., et al. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 2005, 313:578-585.
31. Bendtzen K., Geborek P., Svenson M., et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789.
32. Hanauer S.B., Wagner C.L., Bala M., et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553.
33. Baert F., Noman M., Vermeire S., et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003, 348:601-608.
34. Ainsworth M.A., Bendtzen K., Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008, 103:944-948.
35. Maser E.A., Villela R., Silverberg M.S., Greenberg G.R. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006, 4:1248-1254.
36. Seow C.H., Newman A., Irwin S.P., et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010, 59:49-54.
37. Kopylov U., Mazor Y., Yavzori M., et al. The clinical utility of anti human lambda chain-based ELISA versus double antigen ELISA for the detection of anti-infliximab antibodies. Inflamm Bowel Dis 2012, 18:1628-1633.
38. Karmiris K., Paintaud G., Noman M., et al. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009, 137:1628-1640.
39. West R.L., Zelinkova Z., Wolbink G.J., et al. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008, 28:1122-1126.
40. Sandborn W.J., Colombel J.F., Schreiber S., et al. Dosage adjustment during long-term adalimumab treatment for Crohn's disease: clinical efficacy and pharmacoeconomics. Inflamm Bowel Dis 2011, 17:141-151.
41. Sandborn W.J., Abreu M.T., D'Haens G., et al. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol 2010, 8:688-695.
42. Billioud V., Laharie D., Filippi J., et al. Adherence to adalimumab therapy in Crohn's disease: a French multicenter experience. Inflamm Bowel Dis 2011, 17:152-159.
43. Kopylov U., Mantzaris G.J., Katsanos K.H., et al. The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther 2011, 33:349-357.
44. Katz L., Gisbert J.P., Manoogian B., et al. Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of response. Inflamm Bowel Dis 2012, 18:2026-2033.
45. St.Clair E.W., Wagner C.L., Fasanmade A.A., et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis. Arthritis Rheum 2002, 46:1451-1459.
46. Sandborn W.J., Rutgeerts P., Enns R., et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007, 146:829-838.
47. Ma C., Panaccione R., Heitman S.J., et al. Systematic review: the short-term and long-term efficacy of adalimumab following discontinuation of infliximab. Aliment Pharmacol Ther 2009, 30:977-986.
48. Afif W., Loftus E.V., Faubion W.A., et al. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010, 105:1133-1139.
49. Pariente B., Pineton de Chambrun G., Krzysiek R., et al. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012, 18:1199-1206.
50. Buch M.H., Rubbert-Roth A., Ferraccioli G. To switch or not to switch after a poor response to a TNFα blocker? It is not only a matter of ACR20 OR ACR50. Autoimmun Rev 2012, 11:558-562.
51. Bendtzen K., Ainsworth M., Steenholdt C., et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 13:1-8.
52. Yanai H., Hanauer S. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685-698.
53. Lémann M., Mary J.Y., Duclos B., et al. Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054-1061.
54. Ben-Horin S., Goldstein I., Fudim E., et al. Thiopurines' delayed-onset of the anti-inflammatory effect: early preservation of immune effector functions followed by eventual memory cell depletion. Gut 2009, 58:396-403.
55. Armuzzi A., Marzo M., Felice C., et al. Long-term scheduled therapy with infliximab in inflammatory bowel disease: a single-centre observational study. Gastroenterology 2010, 5:s691-s692.
56. Waugh A.W., Garg S., Matic K., et al. Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort. Aliment Pharmacol Ther 2010, 32:1129-1134.
57. Louis E., Mary J.Y., Vernier-Massouille G., et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012, 142:63-70.
58. Ramos-Casals M., Alvarez R.P., Diaz-Lagares C., Cuadrado M.J., Khamashta M.A., Ramos-Casals M., BIOGEAS Study Group Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev 2010, 9:188-193.
59. Rosenblum H., Amital H. Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 2011, 10:563-568.
60. Ben-Horin S., Mazor Y., Yanai H., et al. The decline of anti-drug antibody titers after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD. Aliment Pharmacol Ther 2012, 35:714-722.